Literature DB >> 22387558

Cutting edge: nitrogen bisphosphonate-induced inflammation is dependent upon mast cells and IL-1.

John T Norton1, Tomoko Hayashi, Brian Crain, John S Cho, Lloyd S Miller, Maripat Corr, Dennis A Carson.   

Abstract

Nitrogen-containing bisphosphonates (NBPs) are taken by millions for bone disorders but may cause serious inflammatory reactions. In this study, we used a murine peritonitis model to characterize the inflammatory mechanisms of these agents. At dosages comparable to those used in humans, injection of NBPs into the peritoneum caused recruitment of neutrophils, followed by an influx of monocytes. These cellular changes corresponded to an initial increase in IL-1α, which preceded a rise in multiple other proinflammatory cytokines. IL-1R, IL-1α, and IL-1β were required for neutrophil recruitment, whereas other MyD88-dependent signaling pathways were needed for the monocyte influx. Mice deficient in mast cells, but not mice lacking lymphocytes, were resistant to NBP-induced inflammation, and reconstitution of these mice with mast cells restored sensitivity to NBPs. These results document the critical role of mast cells and IL-1 in NBP-mediated inflammatory reactions.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22387558      PMCID: PMC3311728          DOI: 10.4049/jimmunol.1100830

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  23 in total

1.  Histidine decarboxylase-stimulating and inflammatory effects of alendronate in mice: involvement of mevalonate pathway, TNFalpha, macrophages, and T-cells.

Authors:  Xue Deng; Zhiqian Yu; Hiromi Funayama; Kouji Yamaguchi; Takashi Sasano; Shunji Sugawara; Yasuo Endo
Journal:  Int Immunopharmacol       Date:  2006-10-16       Impact factor: 4.932

2.  Mutual augmentation of the induction of the histamine-forming enzyme, histidine decarboxylase, between alendronate and immuno-stimulants (IL-1, TNF, and LPS), and its prevention by clodronate.

Authors:  Xue Deng; Zhiqian Yu; Hiromi Funayama; Noriaki Shoji; Takashi Sasano; Yoichiro Iwakura; Shunji Sugawara; Yasuo Endo
Journal:  Toxicol Appl Pharmacol       Date:  2005-10-03       Impact factor: 4.219

3.  Role of resident peritoneal macrophages and mast cells in chemokine production and neutrophil migration in acute inflammation: evidence for an inhibitory loop involving endogenous IL-10.

Authors:  M N Ajuebor; A M Das; L Virág; R J Flower; C Szabó; M Perretti
Journal:  J Immunol       Date:  1999-02-01       Impact factor: 5.422

4.  Cutting edge: critical role for mesothelial cells in necrosis-induced inflammation through the recognition of IL-1 alpha released from dying cells.

Authors:  Tatjana Eigenbrod; Jong-Hwan Park; Jürgen Harder; Yoichiro Iwakura; Gabriel Núñez
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

Review 5.  Bisphosphonate-associated adverse events.

Authors:  Peter D Papapetrou
Journal:  Hormones (Athens)       Date:  2009 Apr-Jun       Impact factor: 2.885

6.  Mast cell-dependent anorexia and hypothermia induced by mucosal activation of Toll-like receptor 7.

Authors:  Tomoko Hayashi; Howard B Cottam; Michael Chan; Guangyi Jin; Rommel I Tawatao; Brian Crain; Lisa Ronacher; Karen Messer; Dennis A Carson; Maripat Corr
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-05-14       Impact factor: 3.619

7.  Inflammasome-mediated disease animal models reveal roles for innate but not adaptive immunity.

Authors:  Susannah D Brydges; James L Mueller; Matthew D McGeough; Carla A Pena; Amirhossein Misaghi; Chhavi Gandhi; Chris D Putnam; David L Boyle; Gary S Firestein; Anthony A Horner; Pejman Soroosh; Wendy T Watford; John J O'Shea; Daniel L Kastner; Hal M Hoffman
Journal:  Immunity       Date:  2009-06-04       Impact factor: 31.745

Review 8.  Lymphocyte development and function in T-cell receptor and RAG-1 mutant mice.

Authors:  P Mombaerts
Journal:  Int Rev Immunol       Date:  1995       Impact factor: 5.311

9.  Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP.

Authors:  Anke J Roelofs; Marjo Jauhiainen; Hannu Mönkkönen; Michael J Rogers; Jukka Mönkkönen; Keith Thompson
Journal:  Br J Haematol       Date:  2008-11-07       Impact factor: 6.998

10.  Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants.

Authors:  Stephanie C Eisenbarth; Oscar R Colegio; William O'Connor; Fayyaz S Sutterwala; Richard A Flavell
Journal:  Nature       Date:  2008-05-21       Impact factor: 49.962

View more
  6 in total

1.  Bisphosphonates target B cells to enhance humoral immune responses.

Authors:  Elena Tonti; Nereida Jiménez de Oya; Gabriele Galliverti; E Ashley Moseman; Pietro Di Lucia; Angelo Amabile; Stefano Sammicheli; Marco De Giovanni; Laura Sironi; Nicolas Chevrier; Giovanni Sitia; Luigi Gennari; Luca G Guidotti; Ulrich H von Andrian; Matteo Iannacone
Journal:  Cell Rep       Date:  2013-10-10       Impact factor: 9.423

2.  Alendronate treatment induces IL-1B expression and apoptosis in glioblastoma cell line.

Authors:  Paola Maura Tricarico; Angeladine Epate; Fulvio Celsi; Sergio Crovella
Journal:  Inflammopharmacology       Date:  2017-06-23       Impact factor: 4.473

3.  The transcription of the alarmin cytokine interleukin-1 alpha is controlled by hypoxia inducible factors 1 and 2 alpha in hypoxic cells.

Authors:  Peleg Rider; Irena Kaplanov; Marianna Romzova; Liora Bernardis; Alex Braiman; Elena Voronov; Ron N Apte
Journal:  Front Immunol       Date:  2012-09-14       Impact factor: 7.561

4.  Intraperitoneal injection of in vitro expanded Vγ9Vδ2 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer.

Authors:  Ikuo Wada; Hirokazu Matsushita; Shuichi Noji; Kazuhiko Mori; Hiroharu Yamashita; Sachiyo Nomura; Nobuyuki Shimizu; Yasuyuki Seto; Kazuhiro Kakimi
Journal:  Cancer Med       Date:  2014-02-07       Impact factor: 4.452

5.  An intrapleural administration of zoledronic acid for inoperable malignant mesothelioma patients: a phase I clinical study protocol.

Authors:  Yuji Tada; Kenzo Hiroshima; Hideaki Shimada; Masato Shingyoji; Toshio Suzuki; Hiroki Umezawa; Ikuo Sekine; Yuichi Takiguchi; Koichiro Tatsumi; Masatoshi Tagawa
Journal:  Springerplus       Date:  2016-02-27

6.  Mevalonate kinase deficiency leads to decreased prenylation of Rab GTPases.

Authors:  Julie Jurczyluk; Marcia A Munoz; Oliver P Skinner; Ryan C Chai; Naveid Ali; Umaimainthan Palendira; Julian Mw Quinn; Alexandra Preston; Stuart G Tangye; Andrew J Brown; Elizabeth Argent; John B Ziegler; Sam Mehr; Michael J Rogers
Journal:  Immunol Cell Biol       Date:  2016-07-05       Impact factor: 5.126

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.